Skip to main content
. Author manuscript; available in PMC: 2015 Oct 12.
Published in final edited form as: J Med Chem. 2015 May 22;58(11):4665–4677. doi: 10.1021/acs.jmedchem.5b00220

Figure 2.

Figure 2

Total anti-METH antibody (mAb7F9 and/or polyclonal) binding shown as the percentage [3H]-METH bound by a 1:50 diluted rat serum sample over time. Dosing times and immunological treatments are denoted below the x-axis (combination treated rats were administered all MCV and mAb treatments). Statistical differences between METH binding in ICKLH-SOO9 + mAb7F9, mAb7F9-only, and ICKLH-SOO9-only treated animals were determined with a two-way repeated measures ANOVA with a post-hoc Bonferroni’s test. For clarity, only statistical analysis comparing ICKLH-SOO9 + mAb7F9 combination group with the other two treatment groups are shown. The * symbol denotes statistical significance compared to mAb7F9 treated animals, and the # symbol denotes statistical significance compared to ICKLH-SOO9 treated animals (p<0.05).